APA (7th ed.) Citation

Lind, M., Ludvigsson, J., Nowak, C., Eriksson, L., Teixeira, P. F., Widman, M., . . . Hannelius, U. (2022, October). Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: The DIAGNODE-3 study protocol. BMJ Open.

Chicago Style (17th ed.) Citation

Lind, Marcus, Johnny Ludvigsson, Christoph Nowak, Linnea Eriksson, Pedro F. Teixeira, Martina Widman, Anton Lindqvist, Rosaura Casas, and Ulf Hannelius. "Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial to Evaluate the Efficacy and Safety of RhGAD65 to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype: The DIAGNODE-3 Study Protocol." BMJ Open Oct. 2022.

MLA (9th ed.) Citation

Lind, Marcus, et al. "Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial to Evaluate the Efficacy and Safety of RhGAD65 to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype: The DIAGNODE-3 Study Protocol." BMJ Open, Oct. 2022.